Oleunor Peri-N4e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The blend supplies the body’s building blocks for protein synthesis and activates cellular pathways such as mTOR that regulate growth and repair. Delivered directly into the bloodstream, the amino acids bypass the digestive tract, allowing rapid utilization for muscle maintenance, immune function, and overall nitrogen balance.

The prescribed dose of Oleunor Peri-N4e is determined by the treating physician based on the patient’s weight, clinical condition, renal function, and nutritional requirements. Dosing regimens are individualized and should follow the prescriber’s specific instructions.

Safety data for Oleunor Peri-N4e in pregnancy or lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Oleunor Peri-N4e, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Oleunor Peri-N4e offers a comprehensive amino‑acid profile that includes both essential and non‑essential amino acids, providing balanced nutrition similar to other high‑quality parenteral formulations. Compared with products that contain only essential amino acids, it may better support overall protein synthesis and metabolic needs in critically ill patients.

Oleunor Peri-N4e should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before administration, inspect for particulate matter and ensure the solution is at room temperature if required by the infusion protocol.

Oleunor Peri-N4e is administered intravenously, typically as an infusion added to a compatible carrier fluid. The rate and duration of infusion are set by the prescribing clinician and should be monitored for tolerance and any adverse reactions.

The most serious risks include anaphylactic reactions, severe electrolyte disturbances, metabolic acidosis, and significant hypotension during infusion. Prompt recognition and management of these events are essential, and patients should be monitored closely throughout administration.

Oleunor Peri-N4e should be avoided in individuals with known hypersensitivity to any of its amino‑acid components or the infusion vehicle. Caution is also advised for patients with severe renal or hepatic impairment, uncontrolled electrolyte disorders, or those at high risk for anaphylaxis.